×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALT – altimmune, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/1
07:44 am
alt
Altimmune announces CEO transition [Seeking Alpha]
Medium
Report
Altimmune announces CEO transition [Seeking Alpha]
12/1
07:30 am
alt
Altimmune Announces CEO Transition and Succession Plan
Medium
Report
Altimmune Announces CEO Transition and Succession Plan
11/26
07:53 am
alt
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
07:30 am
alt
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
08:46 am
alt
Altimmune (NASDAQ:ALT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Altimmune (NASDAQ:ALT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/11
09:21 am
alt
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
Low
Report
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
11/11
08:51 am
alt
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
Low
Report
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
11/7
09:27 am
alt
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
Medium
Report
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/1
08:39 pm
alt
Form 4 Altimmune, Inc. For: Dec 01 Filed by: Durso Jerome Benedict
Medium
Report
Form 4 Altimmune, Inc. For: Dec 01 Filed by: Durso Jerome Benedict
12/1
08:01 am
alt
Form 8-K Altimmune, Inc. For: Nov 30
Medium
Report
Form 8-K Altimmune, Inc. For: Nov 30
11/12
04:07 pm
alt
Form 4 Altimmune, Inc. For: Nov 11 Filed by: WEAVER GREGORY L
Medium
Report
Form 4 Altimmune, Inc. For: Nov 11 Filed by: WEAVER GREGORY L
11/6
04:30 pm
alt
Form 8-K Altimmune, Inc. For: Nov 06
Medium
Report
Form 8-K Altimmune, Inc. For: Nov 06
11/6
04:13 pm
alt
Form 10-Q Altimmune, Inc. For: Sep 30
Medium
Report
Form 10-Q Altimmune, Inc. For: Sep 30
11/6
07:05 am
alt
Form 8-K Altimmune, Inc. For: Nov 06
Low
Report
Form 8-K Altimmune, Inc. For: Nov 06
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
29.8%
3/4 Altimmune (ALT) Presenta At Cowen Health Care Conference - Slideshow [Seeking Alpha] 18.2%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 7.5%
6/12 Form 8-K Altimmune, Inc. For: Jun 10 5.5%
2/4 Form 4 Altimmune, Inc. For: Jan 31 Filed by: Roberts M Scot 3.4%
5/15 Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 1.9%
11/21 Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH 1.8%
4/8 Form 8-K Altimmune, Inc. For: Apr 02 1.8%
6/12 Altimmune Appoints Will Brown as Chief Financial Officer 1.7%
8/14 Form S-8 Altimmune, Inc. 1.5%
3/4 Altimmune (ALT) Presenta At Cowen Health Care Conference - Slideshow [Seeking Alpha] 18.2%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 7.5%
6/12 Form 8-K Altimmune, Inc. For: Jun 10 5.5%
2/4 Form 4 Altimmune, Inc. For: Jan 31 Filed by: Roberts M Scot 3.4%
5/15 Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 1.9%
11/21 Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH 1.8%
4/8 Form 8-K Altimmune, Inc. For: Apr 02 1.8%
6/12 Altimmune Appoints Will Brown as Chief Financial Officer 1.7%
8/14 Form S-8 Altimmune, Inc. 1.5%
TOP News Decliners
3/9
Thinking about buying stock in Aurora Cannabis, Altimmune, Chesapeake Energy Corp, Nokia, or Sprint?
-20.8%
7/9 Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio -14.2%
3/30 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine -13.7%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 -13.4%
1/23 Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer -12.6%
3/3 Form 4 Altimmune, Inc. For: Feb 29 Filed by: Garg Vipin K -12.0%
8/21 Form 8-K Altimmune, Inc. For: Aug 20 -11.7%
11/13 Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update -10.1%
6/10 Altimmune Announces Successful Pre-IND Meeting with FDA -10.0%
6/5 Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs -9.6%
7/9 Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio -14.2%
3/30 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine -13.7%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 -13.4%
1/23 Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer -12.6%
3/3 Form 4 Altimmune, Inc. For: Feb 29 Filed by: Garg Vipin K -12.0%
8/21 Form 8-K Altimmune, Inc. For: Aug 20 -11.7%
11/13 Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update -10.1%
6/10 Altimmune Announces Successful Pre-IND Meeting with FDA -10.0%
6/5 Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs -9.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: